Biotechnology

Innoveren Scientific Announces 510(k) Submission for SkinDisc(TM) Lite

March 6, 2024 8:00 AM

First Commercial Product Submission from Company's Robust Regenerative Medicine-Based Pipeline CINCINNATI, OH / ACCESSWIRE / March 6, 2024 / Innoveren Scientific Inc. (OTCQB:IVRN) ("Innoveren" or the "Company"), a life science company focused on becoming a leading biotech incubator, announced today that it has submitted a 510(k) premarket filing to the U.S. Federal Food and Drug Administration (FDA) for its SkinDiscTM Lite product. SkinDiscTM...

Read more

InDevR Launches Expert Services to Address Vaccine Development Challenges

March 5, 2024 1:30 PM

BOULDER, CO / ACCESSWIRE / March 5, 2024 / InDevR Inc., a global leader in vaccine analytical tools and method development, is excited to announce the launch of its latest offering, Expert Services. Expert Services provides vaccine manufacturers with tailored workflow solutions to help address and eliminate development bottlenecks and accelerate the analysis and validation of seasonal vaccines and novel biotherapeutics. Expert Services is...

Read more

assisTek Celebrates 25 Years of Pioneering Innovation in eClinical Patient Data for Clinical Research Trials

March 5, 2024 10:00 AM

25 Years of Excellence: assisTek Acknowledges Contributions to a Quarter-Century of Success DOYLESTOWN, PA / ACCESSWIRE / March 5, 2024 / assisTek, a trailblazer in eClinical patient data solutions, proudly commemorates a significant milestone: 25 years of revolutionizing the landscape of clinical research trials. Since its inception in 1998, assisTek has been at the forefront of empowering researchers with cutting-edge technologies and...

Read more

Radiance Therapeutics to Attend LSI USA '24 Emerging Medtech Summit in Dana Point, CA

March 5, 2024 9:00 AM

EMERYVILLE, CA / ACCESSWIRE / March 5, 2024 / Radiance Therapeutics, Inc. (RadianceTx®), an innovation leader in ophthalmic devices, is delighted to announce that its CEO, Laurence Marsteller MD, will be representing the company at the LSI USA '24 Emerging Medtech Summit, which will take place on March 18-22, 2024 in Dana Point, California. LSI USA ‘24 is a unique conference that brings together the most innovative emerging medtech players and...

Read more

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

March 5, 2024 8:31 AM

Tharimmune invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference BRIDGEWATER, NJ / ACCESSWIRE / March 5, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology is pleased to announce that it has been...

Read more

Edesa Biotech to Participate in Upcoming Dermatology Meetings

March 4, 2024 4:30 PM

TORONTO, ON / ACCESSWIRE / March 4, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company plans to participate in the American Contact Dermatitis Society Annual Meeting on March 7, 2024 and the American Academy of Dermatology Annual Meeting from March 8-12, 2024 in San Diego, California. Attendees...

Read more

Organicell Regenerative Medicine Rebranding to ZEO ScientifiX

March 4, 2024 4:15 PM

Leading Therapeutics Research Company Begins New Era Common Stock to trade on OTCQB under the symbol "ZEOX" commencing March 5, 2024 FORT LAUDERDALE, FL / ACCESSWIRE / March 4, 2024 / ZEO ScientifiX, Inc. (OTCQB:ZEOX) (f/k/a Organicell Regenerative Medicine, Inc. - OTCQB: OCEL) today reported that the Financial Industry Regulatory Agency ("FINRA") completed the processing of the Company's Corporate Action Notification Form filed with respect to...

Read more

Adolore BioTherapeutics Announces Issuance of First U.S. Patent Covering CA8* Gene Therapies to Treat Chronic Pain

March 4, 2024 10:00 AM

Patent and CA8* gene therapy technology licensed by Adolore BioTherapeutics from the University of Miami Company advancing development of rdHSV-CA8* gene therapy for the treatment of chronic osteoarthritis (OA) knee pain toward an IND DELRAY BEACH, FL / ACCESSWIRE / March 4, 2024 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain,...

Read more

Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment

March 4, 2024 6:20 AM

Berlin Cures, a clinical-stage biotechnology firm, advances innovative treatment aimed at combating Long COVID, currently impacting over 100 million people globally. Over 50% of patients in randomized placebo-controlled Phase-II-trial now recruited; no issues regarding safety observed. Berlin Cures innovative platform develops novel aptamer-based drugs to neutralize pathogenic functional autoantibodies, targeting diseases. BERLIN, GERMANY /...

Read more

AbTherx Announces Transition from Early Access to Commercialization of its Bispecific and Full Human Diversity Antibody Discovery Technologies

March 4, 2024 6:00 AM

Atlas™ Mice can now be evaluated by pharmaceutical and biotech companies and accessed through a network of preferred service providers MOUNTAIN VIEW, CA / ACCESSWIRE / March 4, 2024 / AbTherx, a biotechnology company with innovative technologies that enable and accelerate antibody discovery, today announced expanded commercialization of its bispecific and full human diversity antibody discovery technologies. After an initial successful launch...

Read more

MRES: M2Bio Sciences Provides Corporate Update

March 1, 2024 9:10 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / March 1, 2024 / Institute of Biomedical Research Corporation (OTC PINK:MRES) is pleased to provide further details of the sale to Real American Capital Corporation (OTC PINK:RLAB) of 100% ownership of the concept, business model, contacts and contracts that collectively can be used to establish a mixed martial arts league and are herein referred to as "M2MMA" (https://m2mma.com). The transaction was...

Read more

NovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of Shareholders

March 1, 2024 9:00 AM

CLEVELAND, OH / ACCESSWIRE / March 1, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today provided an update on business developments, financing and the 2024 annual meeting. The previously disclosed $10.7 million financing transaction with Sumner Global LLC remains pending, as Sumner Global has not yet obtained the funding necessary to close the transaction. To provide...

Read more

enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

February 29, 2024 4:15 PM

$46.4 million cash and investments on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025 Topline efficacy data for VenoValve® U.S. pivotal trial to be presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024 Continued progress toward launch of GLP study for enVVe® transcatheter-based replacement venous valve IRVINE, CA / ACCESSWIRE / February 29, 2024 /...

Read more

Hemogenyx Pharmaceuticals PLC Announces Placing to Raise US$4.2 million

February 29, 2024 2:00 AM

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UKMAR"). MARKET SOUNDINGS WERE TAKEN IN...

Read more

Form Bio and Ginkgo Partner to Develop Industry-Leading Solutions for AAV Gene Therapy Design and Development

February 28, 2024 7:01 AM

Combined Solution Set Addresses Critical Hurdles in Bringing Gene Therapy Products to IND DALLAS, TX / ACCESSWIRE / February 28, 2024 / Form Bio, the breakthrough computational life sciences solutions provider, and Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, today announced a new partnership to provide a complete and holistic solution offering for AAV gene therapy design and development. The...

Read more

Year-end Report 2023

February 28, 2024 2:20 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / February 28, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, February 28, 2024- Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), publishes the year-end report 2023. Important events during the fourth quarter In October, Vicore announced the results from the Phase 1 study of C106. Further development of...

Read more

Relief Therapeutics Renews CHF 50 million Share Subscription Facility

February 28, 2024 1:00 AM

3-year CHF 50 million capital commitment from GEM Relief advances strategic transformation GENEVA, SWITZERLAND / ACCESSWIRE / February 28, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the renewal of its CHF 50 million Share Subscription Facility...

Read more

Prolocor Announces $1.7 Million in Bridge Funding

February 27, 2024 9:00 AM

Green Park & Golf Ventures and Labcorp continue to demonstrate ongoing commitment to Prolocor initiatives. Funding will be used for ongoing clinical program and commercialization in 2024. PHILADELPHIA, PA / ACCESSWIRE / February 27, 2024 / Prolocor, Inc., a healthcare startup developing an innovative precision diagnostic test with the potential to predict the risk of thrombosis by quantifying FcγRIIa (pFCG test), today announced that they have...

Read more

Vicore to Present at Upcoming Investor Conferences

February 27, 2024 2:20 AM

STOCKHOLM, SE / ACCESSWIRE / February 27, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, February 27, 2024 - Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following investor conferences: TD Cowen 44th Annual Health Care Conference Location: Boston, MA. Presenter: Ahmed Mousa, CEO Presentation Date and Time:...

Read more

ScaiPod: Revolutionizing Immuno-Oncology With Multi-Omics and AI at Scale

February 26, 2024 10:05 AM

BASEL, SWITZERLAND / ACCESSWIRE / February 26, 2024 / Scailyte is thrilled to announce ScaiPod, a moonshot initiative to solve some of the toughest clinical challenges in immuno-oncology. ScaiPod's mission is to fuel the development of a new generation of clinical biomarkers predictive for the response to immune checkpoint inhibitors (ICI) and thus to enable precision immuno-oncology. Additionally, it will unravel mechanistic insights related to...

Read more